560 related articles for article (PubMed ID: 12173016)
21. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer.
Adams S; Baum RP; Stuckensen T; Bitter K; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1255-60. PubMed ID: 9724374
[TBL] [Abstract][Full Text] [Related]
22. The real additional value of FDG-PET in detecting the occult primary tumour in patients with cervical lymph node metastases of unknown primary tumour.
de Bree R
Eur Arch Otorhinolaryngol; 2010 Nov; 267(11):1653-5. PubMed ID: 20827553
[No Abstract] [Full Text] [Related]
23. Cervical lymph node metastases of squamous cell carcinoma of unknown origin: the diagnostic value of FDG PET/CT and clinical outcome.
Dale E; Moan JM; Osnes TA; Bogsrud TV
Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):1015-1019. PubMed ID: 27671150
[TBL] [Abstract][Full Text] [Related]
24. The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor.
Fogarty GB; Peters LJ; Stewart J; Scott C; Rischin D; Hicks RJ
Head Neck; 2003 Feb; 25(2):138-45. PubMed ID: 12509797
[TBL] [Abstract][Full Text] [Related]
25. Value of fused positron emission tomography CT in detecting primaries in patients with primary unknown cervical lymph node metastasis.
Chen YH; Yang XM; Li SS; Wang YH; He JJ; Yang YD; Wang S; Liu JJ; Zhang XL
J Med Imaging Radiat Oncol; 2012 Feb; 56(1):66-74. PubMed ID: 22339748
[TBL] [Abstract][Full Text] [Related]
26. FDG PET and PET/CT for the detection of the primary tumour in patients with cervical non-squamous cell carcinoma metastasis of an unknown primary.
Paul SA; Stoeckli SJ; von Schulthess GK; Goerres GW
Eur Arch Otorhinolaryngol; 2007 Feb; 264(2):189-95. PubMed ID: 17177026
[TBL] [Abstract][Full Text] [Related]
27. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN
Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604
[TBL] [Abstract][Full Text] [Related]
28. The added value of 18F-fluorodeoxyglucose positron emission tomography computed tomography in patients with neck lymph node metastases from an unknown primary malignancy.
Prowse SJ; Shaw R; Ganeshan D; Prowse PM; Hanlon R; Lewis-Jones H; Wieshmann H
J Laryngol Otol; 2013 Aug; 127(8):780-7. PubMed ID: 23919968
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site.
Cianchetti M; Mancuso AA; Amdur RJ; Werning JW; Kirwan J; Morris CG; Mendenhall WM
Laryngoscope; 2009 Dec; 119(12):2348-54. PubMed ID: 19718744
[TBL] [Abstract][Full Text] [Related]
30. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
[TBL] [Abstract][Full Text] [Related]
31. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors.
AAssar OS; Fischbein NJ; Caputo GR; Kaplan MJ; Price DC; Singer MI; Dillon WP; Hawkins RA
Radiology; 1999 Jan; 210(1):177-81. PubMed ID: 9885604
[TBL] [Abstract][Full Text] [Related]
32. Lymph node metastasis of squamous cell carcinoma from an unknown primary in the upper and middle neck: Impact of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography.
Deron PB; Bonte KM; Vermeersch HF; Van de Wiele C
Cancer Biother Radiopharm; 2011 Jun; 26(3):331-4. PubMed ID: 21711095
[TBL] [Abstract][Full Text] [Related]
33. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis.
Kyzas PA; Evangelou E; Denaxa-Kyza D; Ioannidis JP
J Natl Cancer Inst; 2008 May; 100(10):712-20. PubMed ID: 18477804
[TBL] [Abstract][Full Text] [Related]
34. Role of 18-Fludeoxyglucose positron emission tomography-computed tomography and subsequent panendoscopy in head and neck squamous cell carcinoma of unknown primary.
Mani N; George MM; Nash L; Anwar B; Homer JJ
Laryngoscope; 2016 Jun; 126(6):1354-8. PubMed ID: 26671043
[TBL] [Abstract][Full Text] [Related]
35. ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography as an effective diagnostic workup in cervical metastasis of carcinoma from an unknown primary tumor.
Zhao K; Luo XM; Zhou SH; Liu JH; Yan SX; Lu ZJ; Yang SY; Lin LL; Dong MJ
Cancer Biother Radiopharm; 2012 Dec; 27(10):685-93. PubMed ID: 22834634
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic work-up and outcome of cervical metastases from an unknown primary.
Guntinas-Lichius O; Peter Klussmann J; Dinh S; Dinh M; Schmidt M; Semrau R; Mueller RP
Acta Otolaryngol; 2006 May; 126(5):536-44. PubMed ID: 16698706
[TBL] [Abstract][Full Text] [Related]
37. [Results of pretherapeutic lymph node diagnosis in head and neck tumors. Clinical value of 18-FDG positron emission tomography (PET)].
Di Martino E; Nowak B; Krombach GA; Sellhaus B; Hausmann R; Cremerius U; Büll U; Westhofen M
Laryngorhinootologie; 2000 Apr; 79(4):201-6. PubMed ID: 10838683
[TBL] [Abstract][Full Text] [Related]
38. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Han A; Xue J; Hu M; Zheng J; Wang X
Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
[TBL] [Abstract][Full Text] [Related]
39. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
40. Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET?
Brouwer J; Senft A; de Bree R; Comans EF; Golding RP; Castelijns JA; Hoekstra OS; Leemans CR
Oral Oncol; 2006 Mar; 42(3):275-80. PubMed ID: 16266820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
